- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00565682
Pain Post Abdominal Laparoscopy Prevention With Arcoxia
November 29, 2007 updated by: Hospital Vozandez
To test the analgesic efficacy of etoricoxib used before a surgical procedure compared to the already known effect when administered after such a procedure.
Patient will be receiving either etoricoxib or the respective placebo one hour before surgery, then two hours after those receiving the active will receive placebo and those that received placebo will be given etoricoxib.
Pain score measurements will be performed sequentially.
Rescue medication will be available all the time.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Voluntary acceptance to participate in the study and signed the informed consent form
- Age older than 18 years old and younger than 70 years
- Diagnosis of appendicitis, cholecystitis or ovarian cysts suitable of laparoscopic surgery
Exclusion Criteria:
- Age less than 18 years or older than 70 years.
- Laparoscopic procedures for diagnostic purposes.
- Current use of anticoagulants.
- Known hypersensitivity to etoricoxib or its components.
- History of a CABG or MI (less than 1 year)
- History of unstable angina (over the past six months).
- Current inflammatory bowel disease.
- Uncontrolled hypertension or heart failure
- Renal dysfunction/impairment (creatinine clearance < 30ml/min)
- Cirrhosis or severe hepatic dysfunction
- Any degree of dehydration (mild to severe)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
Etoricoxib 120 mg
|
etoricoxib 120 mg, tablet, orally, OD
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure the amount of rescue medication (opioid) needed to relief
Time Frame: Every hour after surgery
|
Every hour after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the overall analgesic effect using the visual analog scale (VAS)
Time Frame: Every hour after surgery
|
Every hour after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Eduardo Noboa, MD, Hospital Vozandez
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2006
Study Completion (Actual)
December 1, 2006
Study Registration Dates
First Submitted
November 29, 2007
First Submitted That Met QC Criteria
November 29, 2007
First Posted (Estimate)
November 30, 2007
Study Record Updates
Last Update Posted (Estimate)
November 30, 2007
Last Update Submitted That Met QC Criteria
November 29, 2007
Last Verified
November 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Infections
- Neoplasms
- Endocrine System Diseases
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Gallbladder Diseases
- Biliary Tract Diseases
- Cecal Diseases
- Intraabdominal Infections
- Cholecystitis
- Appendicitis
- Ovarian Cysts
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Etoricoxib
Other Study ID Numbers
- DOLAAR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Laparoscopic Surgery for Appendicitis
-
Cantonal Hosptal, BasellandUnknownIndication for Laparoscopic Surgery (Any)Switzerland
-
University Hospital DubravaCompletedLaparoscopic Surgery | Appendicitis AcuteCroatia
-
Unity Health TorontoCompletedLaparoscopic Hysterectomy for Benign ConditionsCanada
-
Royal College of Surgeons, IrelandNot yet recruitingPain | Analgesia | Surgery | Appendicitis | Laparoscopic | Bupivacaine
-
Sefako Makgatho Health Sciences UniversityCompletedLaparoscopic Surgery | Laparoscopic Entry Technique
-
Case Comprehensive Cancer CenterCompletedLaparoscopic Surgery | Vaginal SurgeryUnited States
-
Copenhagen Academy for Medical Education and SimulationCompleted
-
Aga Khan UniversityCompletedSubcostal TAP Block for Multiport Laparoscopic Cholecystectomy
-
Zagazig UniversityCompletedSepsis | Laparoscopic Surgery | Abdominal Abscess | Acute Appendicitis With RuptureEgypt
-
Qianfoshan HospitalNot yet recruiting
Clinical Trials on etoricoxib 120 mg
-
Organon and CoCompleted
-
Darnitsa Pharmaceutical CompanyAnapharm BioanalyticsCompletedHealthy Subjects | BioequivalenceTurkey
-
Organon and CoCompletedAcute Pain Following a Total Abdominal Hysterectomy
-
Organon and CoCompleted
-
Hoffmann-La RocheChugai Pharmaceutical Co.TerminatedNeuromyelitis Optica Spectrum Disorder | NMOSDUnited States, Korea, Republic of, Italy, Canada, Japan, Turkey
-
Organon and CoCompleted
-
Pharmtechnology LLCClinPharmInvest, LLCNot yet recruitingBioequivalenceRussian Federation
-
IpsenRecruitingPrimary Sclerosing CholangitisUnited States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
-
Eli Lilly and CompanyActive, not recruitingNeoplasms, HematologicUnited States, Germany, Australia, Sweden, France, Spain, Italy, Austria, Canada
-
Organon and CoCompleted